Introduction of rotavirus vaccination in Palestine: An evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 19 09 2019
accepted: 16 01 2020
entrez: 6 2 2020
pubmed: 6 2 2020
medline: 1 5 2020
Statut: epublish

Résumé

The Palestinian Ministry of Health (MOH) started a routine rotavirus immunization program with ROTARIX in May 2016, with support for vaccine procurement and introduction provided through a global development organization. In 2018, financial responsibility for rotavirus vaccine procurement was transferred to the Palestinian government, which elected to shift to ROTAVAC vaccine because of its lower price per dose. This study aims to assess the cost, impact, and cost-effectiveness of rotavirus vaccination, specifically evaluating the economic implications of the change in vaccine product, accounting for the different characteristics of each rotavirus vaccine used. We conducted primary and secondary data collection to assess the introduction, procurement, supply chain, and service delivery costs related to each vaccine. We used the UNIVAC model to project costs and benefits of rotavirus vaccination over a 10-year period comparing the use of ROTARIX versus no vaccination; ROTAVAC versus no vaccination; and ROTAVAC versus ROTARIX. We undertook scenario and probabilistic analyses to capture uncertainty in some of the study parameters. We used a 3% discount rate, and all costs are in 2018 US$. The cost to deliver one dose was lower for ROTAVAC than ROTARIX (US$2.36 versus $2.70), but the total cost per course, excluding vaccine cost, favored ROTARIX ($7.09 versus $5.39). Both vaccines had high probability of being cost-effective interventions in Palestine compared to no vaccine. Because of lower vaccination program costs for ROTAVAC, however, switching from ROTARIX to ROTAVAC was cost-saving. National decision-makers should consider systematically assessing multiple criteria beyond vaccine price when comparing the health and economic value of several products in order to fully account for all characteristics including product presentation, number of doses per course, cold chain volume, cost of delivery, and wastage.

Identifiants

pubmed: 32023295
doi: 10.1371/journal.pone.0228506
pii: PONE-D-19-26427
pmc: PMC7001920
doi:

Substances chimiques

Rotavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0228506

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2009 Jun 26;4(6):e6060
pubmed: 19557133
Emerg Infect Dis. 2003 May;9(5):565-72
pubmed: 12737740
Vaccine. 2013 Jul 02;31 Suppl 3:C19-29
pubmed: 23777686
Lancet Glob Health. 2019 Nov;7(11):e1541-e1552
pubmed: 31607466
Vaccine. 2015 May 7;33 Suppl 1:A192-200
pubmed: 25919160
Lancet Infect Dis. 2017 Sep;17(9):909-948
pubmed: 28579426
Wkly Epidemiol Rec. 2013 Feb 1;88(5):49-64
pubmed: 23424730
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
Int J Health Plann Manage. 2013 Oct-Dec;28(4):320-32
pubmed: 23125096
Vaccine. 2017 Oct 27;35(45):6047-6058
pubmed: 28986034
Vaccine. 2018 Dec 14;36(51):7780-7789
pubmed: 30007826
Clin Infect Dis. 2019 Aug 30;69(6):1071-1078
pubmed: 30689799
Lancet. 2014 Jun 21;383(9935):2136-43
pubmed: 24629994
Lancet. 2013 Apr 20;381(9875):1405-1416
pubmed: 23582727
Lancet Glob Health. 2015 Nov;3(11):e712-23
pubmed: 26475018
Clin Infect Dis. 2016 May 1;62 Suppl 2:S96-S105
pubmed: 27059362
Vaccine. 2016 Jul 29;34(35):4213-4220
pubmed: 27371102
J Public Health (Oxf). 2019 Mar 1;41(1):e78-e83
pubmed: 29917158
Vaccine. 2018 Nov 26;36(49):7472-7478
pubmed: 30420039
J Health Popul Nutr. 2015 Mar;33(1):1-8
pubmed: 25995716
Lancet Infect Dis. 2019 Jul;19(7):717-727
pubmed: 31178289
J Infect Dis. 2010 Sep 1;202 Suppl:S12-22
pubmed: 20684691
Vaccine. 2018 Dec 14;36(51):7769-7774
pubmed: 29107346
Vaccine. 2019 Feb 4;37(6):798-807
pubmed: 30639458
Vaccine. 2015 Dec 16;33(51):7357-7363
pubmed: 26519548

Auteurs

Samer Jaber (S)

Palestinian Ministry of Health, Nablus, West Bank.

Yaser Bouzya (Y)

Palestinian Ministry of Health, Ramallah, West Bank.

Jehad Sabbah (J)

United Nations Relief and Works Agency for Palestine Refugees in the Middle East, East Jerusalem, Palestinian Territory.

Mustafa Barham (M)

Rostropovich-Vishnevskaya Foundation, Ramallah, West Bank.

Fakhr Abu-Awwad (F)

Rostropovich-Vishnevskaya Foundation, Gaza City, Gaza.

Diaa Hjaija (D)

Palestinian Ministry of Health, Ramallah, West Bank.

Assad Ramlawi (A)

Palestinian Ministry of Health, Ramallah, West Bank.

Clint Pecenka (C)

PATH, Seattle, Washington, United States of America.

Andrew Clark (A)

London School of Hygiene and Tropical Medicine, London, United Kingdom.

Mercy Mvundura (M)

PATH, Seattle, Washington, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH